In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $129.71, down -2.07% from its previous closing price of $132.45. In other words, the price has decreased by -$2.07 from its previous closing price. On the day, 0.96 million shares were traded. TMDX stock price reached its highest trading level at $133.35 during the session, while it also had its lowest trading level at $129.56.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 254.86. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 06 ’25 when Hassanein Waleed H bought 8,400 shares for $118.68 per share. The transaction valued at 996,912 led to the insider holds 477,759 shares of the business.
Hassanein Waleed H bought 8,475 shares of TMDX for $985,209 on Aug 07 ’25. The President & CEO now owns 486,234 shares after completing the transaction at $116.25 per share. On Aug 04 ’25, another insider, Basile Edward M, who serves as the Director of the company, sold 4,143 shares for $125.51 each. As a result, the insider received 519,988 and left with 2,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4421860352 and an Enterprise Value of 4540107264. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.08, and their Forward P/E ratio for the next fiscal year is 46.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.32 while its Price-to-Book (P/B) ratio in mrq is 13.88. Its current Enterprise Value per Revenue stands at 8.545 whereas that against EBITDA is 45.264.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.04, which has changed by 0.6168213 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $145.50, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 11.46%, while the 200-Day Moving Average is calculated to be 27.42%.
Shares Statistics:
It appears that TMDX traded 1.04M shares on average per day over the past three months and 881540 shares per day over the past ten days. A total of 34.04M shares are outstanding, with a floating share count of 32.94M. Insiders hold about 3.36% of the company’s shares, while institutions hold 109.57% stake in the company. Shares short for TMDX as of 1760486400 were 7971237 with a Short Ratio of 7.69, compared to 1757894400 on 8394299. Therefore, it implies a Short% of Shares Outstanding of 7971237 and a Short% of Float of 40.17.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Transmedics Group Inc (TMDX).The consensus estimate for the next quarter is $0.41, with high estimates of $0.47 and low estimates of $0.29.
Analysts are recommending an EPS of between $2.58 and $2.1 for the fiscal current year, implying an average EPS of $2.33. EPS for the following year is $2.88, with 8.0 analysts recommending between $3.55 and $2.2.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $144.76M. It ranges from a high estimate of $148.6M to a low estimate of $139.4M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $108.76MFor the next quarter, 11 analysts are estimating revenue of $155.57M. There is a high estimate of $159.8M for the next quarter, whereas the lowest estimate is $148.61M.
A total of 12 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $605M, while the lowest revenue estimate was $594.6M, resulting in an average revenue estimate of $600.52M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $725.98M in the next fiscal year. The high estimate is $764M and the low estimate is $687.4M.
